Aprepitant

USDailyMed:Aprepitant AU:B1 A04AD12(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only 5-([(2R,3S)-2-((R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)morpholino]methyl)-1H-1,2,4-triazol-3(2H)-one 170729-80-3Y 6918365 3490 DB00673Y 5293568Y 1NF15YR6UY CHEBI:499361Y ChEMBL1471Y DTXSID3049047 Interactive image FC(F)(F)c1cc(cc(c1)C(F)(F)F)[C@H](O[C@H]4OCCN(CC/2=N/C(=O)NN\2)[C@H]4c3ccc(F)cc3)C InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1YKey:ATALOFNDEOCMKK-OITMNORJSA-NY Aprepitant, sold under the brand nameEmendamong others, is a medication used to preventchemotherapy-induced nausea and vomitingand to preventpostoperative nausea and vomiting.It may be used together withondansetronanddexamethasone.It is takenby mouthor administered by intravenous injection.Aprodrug,fosaprepitant, is also available for intravenous administration. Common side effects include tiredness, loss of appetite, diarrhea, abdominal pain, hiccups, itchiness, pneumonia, and blood pressure changes.Other severe side effects may includeanaphylaxis.While use inpregnancydoes not appear to be harmful, such use has not been well studied.Aprepitant belongs to the class ofneurokinin-1 receptor antagonists.It works by blockingsubstance Pfrom attaching to theNK1receptors. Aprepitant was approved for medical use in the European Union and the United States in 2003.It is made byMerck & Co.It is on theWorld Health Organization's List of Essential Medicines.